​

CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CRSP Stock Forecast

CRISPR Therapeutics (CRSP) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $75.67, with a high of $95.00 and a low of $65.00. This represents a 100.34% increase from the last price of $37.77.

$35 $47 $59 $71 $83 $95 High: $95 Avg: $75.67 Low: $65 Last Closed Price: $37.77

CRSP Stock Rating

CRISPR Therapeutics stock's rating consensus is Buy, based on 29 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (72.41%), 7 Hold (24.14%), 1 Sell (3.45%), and 0 Strong Sell (0.00%).

Buy
Total 29 1 7 21 Strong Sell Sell Hold Buy Strong Buy

CRSP Price Target Upside V Benchmarks

TypeNameUpside
StockCRISPR Therapeutics100.34%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-18
Avg Price Target-$65.00$72.75
Last Closing Price$37.77$37.77$37.77
Upside/Downside-72.09%92.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25512111-29
Mar, 25512111-29
Feb, 25511112-29
Jan, 25411112-28
Dec, 24411112129
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2025Mitchell KapoorH.C. Wainwright$65.00$40.0062.50%72.09%
Nov 06, 2024Jay OlsonOppenheimer$95.00$49.5191.88%151.52%
Nov 05, 2024Rick BienkowskiLeerink Partners$67.00$50.3633.04%77.39%
Aug 12, 2024Joon LeeTruist Financial$100.00$46.55114.82%164.76%
Aug 06, 2024Gil BlumNeedham$84.00$50.1167.63%122.40%
Aug 06, 2024Benjamin BurnettStifel Nicolaus$59.00$50.0117.98%56.21%
Aug 06, 2024Luca IssiRBC Capital$60.00$50.1319.69%58.86%
May 09, 2024Jack AllenRobert W. Baird$52.00$53.29-2.42%37.68%
Nov 23, 2022Citigroup$63.00$55.7213.07%66.80%
Aug 09, 2022Geulah LivshitsChardan Capital$79.30$81.39-2.57%109.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Leerink PartnersOutperformOutperformhold
Aug 06, 2024Cowen & Co.SellSellhold
Aug 06, 2024NeedhamBuyBuyhold
Aug 06, 2024RBC CapitalSector PerformSector Performhold
Jun 17, 2024Piper SandlerOverweightOverweighthold
Apr 18, 2024CitigroupBuyBuyhold
Feb 15, 2024Wolfe ResearchPeer Performinitialise
Dec 11, 2023JMP SecuritiesMarket OutperformMarket Outperformhold
Oct 17, 2023Cantor FitzgeraldOverweightNeutraldowngrade
Aug 17, 2023CitigroupNeutralBuyupgrade

Financial Forecast

EPS Forecast

$-50 $-31 $-12 $7 $26 $45 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.29$4.97$-8.36$-1.94$-4.34----
Avg Forecast$-5.02$4.88$-9.09$-2.92$-5.17$-5.07$-3.12$-1.00$1.71
High Forecast$0.70$44.49$2.49$-1.60$-4.73$-3.01$8.56$9.76$7.17
Low Forecast$-45.76$-0.68$-36.12$-4.16$-6.53$-6.60$-7.69$-5.76$-0.47
Surprise %5.38%1.84%-8.03%-33.56%-16.05%----

Revenue Forecast

$0 $1B $3B $4B $6B $7B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$543.00K$913.08M$436.00K$371.21M$37.31M----
Avg Forecast$2.32M$903.86M$6.14M$293.21M$11.13M$118.69M$506.62M$1.02B$1.69B
High Forecast$16.78M$6.54B$20.20M$377.05M$36.07M$410.38M$516.62M$1.04B$5.85B
Low Forecast$287.31K$112.01M$122.50K$173.24M$1.21M$2.49M$496.61M$1.01B$35.48M
Surprise %-76.58%1.02%-92.90%26.60%235.12%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-348.87M$377.66M$-650.17M$-153.61M$-366.25M----
Avg Forecast$-282.52M$338.20M$-603.01M$-153.61M$-445.92M$-448.97M$-262.09M$-119.23M$135.47M
High Forecast$-226.02M$554.59M$-482.41M$-122.89M$-374.41M$-238.06M$678.45M$773.32M$568.30M
Low Forecast$-339.03M$121.81M$-723.61M$-184.33M$-517.43M$-522.52M$-609.51M$-456.49M$-36.95M
Surprise %23.48%11.67%7.82%--17.87%----

CRSP Forecast FAQ

Is CRISPR Therapeutics stock a buy?

CRISPR Therapeutics stock has a consensus rating of Buy, based on 29 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that CRISPR Therapeutics is a favorable investment for most analysts.

What is CRISPR Therapeutics's price target?

CRISPR Therapeutics's price target, set by 29 Wall Street analysts, averages $75.67 over the next 12 months. The price target range spans from $65 at the low end to $95 at the high end, suggesting a potential 100.34% change from the previous closing price of $37.77.

How does CRISPR Therapeutics stock forecast compare to its benchmarks?

CRISPR Therapeutics's stock forecast shows a 100.34% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for CRISPR Therapeutics over the past three months?

  • April 2025: 17.24% Strong Buy, 41.38% Buy, 37.93% Hold, 3.45% Sell, 0% Strong Sell.
  • March 2025: 17.24% Strong Buy, 41.38% Buy, 37.93% Hold, 3.45% Sell, 0% Strong Sell.
  • February 2025: 17.24% Strong Buy, 37.93% Buy, 37.93% Hold, 6.90% Sell, 0% Strong Sell.

What is CRISPR Therapeutics’s EPS forecast?

CRISPR Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.07, marking a 16.82% increase from the reported $-4.34 in 2024. Estimates for the following years are $-3.12 in 2026, $-1 in 2027, and $1.71 in 2028.

What is CRISPR Therapeutics’s revenue forecast?

CRISPR Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $118.69M, reflecting a 218.07% increase from the reported $37.31M in 2024. The forecast for 2026 is $506.62M, followed by $1.02B for 2027, and $1.69B for 2028.

What is CRISPR Therapeutics’s net income forecast?

CRISPR Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-449M, representing an 22.58% increase from the reported $-366M in 2024. Projections indicate $-262M in 2026, $-119M in 2027, and $135.47M in 2028.